Target Name: MIR376A1
NCBI ID: G494325
Review Report on MIR376A1 Target / Biomarker Content of Review Report on MIR376A1 Target / Biomarker
MIR376A1
Other Name(s): hsa-mir-376a-1 | hsa-miR-376a-5p | microRNA 376a-1 | MIR376A-1 | MIRN376A-1 | MIRN376A | MicroRNA 376a-1 | hsa-miR-376a-3p | MIRN376A1 | mir-376a-1

MIR376A1: A Potential Drug Target and Biomarker

MIR376A1, a protein encoded by the human gene HTTN1, is a potential drug target and biomarker associated with various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. Its function and interactions with other proteins have been extensively studied, providing insights into its potential as a therapeutic target or diagnostic marker.

MIR376A1 is a non-coding RNA molecule that has been shown to play a critical role in various cellular processes, including cell growth, differentiation, and survival. It is a part of the microRNA (miRNA) family, a set of small non-coding RNAs that are involved in post-transcriptional gene regulation. miRNAs have been shown to regulate gene expression by binding to specific target genes, often leading to the targeted translation of mRNAs for degradation or degradation-inducing translation.

MIR376A1 has been shown to regulate the expression of various genes, including those involved in cell growth, differentiation, and apoptosis. It has been shown to promote the translation of survival-related genes, such as Bcl-2, which is known to play a critical role in preventing apoptosis and promoting cell survival. MIR376A1 has also been shown to repress the translation of pro-apoptotic genes, including p53, which is involved in the regulation of cell cycle and apoptosis.

In addition to its role in cell survival, MIR376A1 has also been shown to be involved in the regulation of cell proliferation. It has been shown to promote the growth of various types of cancer cells and to contribute to the development of various types of cancer. This is thought to be achieved by regulating the translation of genes involved in cell growth and proliferation, such as the TGF-β pathway.

MIR376A1 has also been shown to be involved in the regulation of cellular processes related to neurodegenerative disorders. It has been shown to contribute to the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. This is thought to be achieved by regulating the translation of genes involved in neurodegeneration, such as the 尾-amyloid (尾-amyloid) pathway.

In addition to its role in neurodegenerative diseases, MIR376A1 has also been shown to be involved in the regulation of cardiovascular diseases. It has been shown to contribute to the development and progression of cardiovascular diseases, including heart failure and hypertension. This is thought to be Achieved by regulating the translation of genes involved in cardiovascular function, such as the angiotensin-converting enzyme (ACE) pathway.

MIR376A1 is a potential drug target due to its involvement in various cellular processes that are related to the development and progression of various diseases. Its role in cell survival and proliferation, as well as its involvement in the regulation of neurodegenerative and cardiovascular diseases, make it an attractive target for therapeutic intervention. Further research is needed to fully understand the role of MIR376A1 in these diseases and to develop effective treatments based on this understanding.

Protein Name: MicroRNA 376a-1

The "MIR376A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR376A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR376A2 | MIR376B | MIR376C | MIR377 | MIR378A | MIR378B | MIR378C | MIR378D1 | MIR378D2 | MIR378E | MIR378F | MIR378G | MIR378H | MIR378I | MIR379 | MIR380 | MIR381 | MIR382 | MIR383 | MIR384 | MIR3907 | MIR3908 | MIR3909 | MIR3910-1 | MIR3910-2 | MIR3911 | MIR3912 | MIR3913-1 | MIR3913-2 | MIR3914-1 | MIR3914-2 | MIR3915 | MIR3916 | MIR3917 | MIR3918 | MIR3919 | MIR3920 | MIR3921 | MIR3922 | MIR3923 | MIR3924 | MIR3925 | MIR3926-1 | MIR3926-2 | MIR3927 | MIR3928 | MIR3929 | MIR3934 | MIR3935 | MIR3936 | MIR3936HG | MIR3937 | MIR3938 | MIR3939 | MIR3940 | MIR3941 | MIR3942 | MIR3943 | MIR3944 | MIR3945 | MIR3945HG | MIR3960 | MIR3972 | MIR3973 | MIR3974 | MIR3976 | MIR3976HG | MIR3977 | MIR3978 | MIR409 | MIR410 | MIR411 | MIR412 | MIR421 | MIR422A | MIR423 | MIR424 | MIR425 | MIR4251 | MIR4252 | MIR4253 | MIR4254 | MIR4255 | MIR4256 | MIR4257 | MIR4258 | MIR4259 | MIR4260 | MIR4261 | MIR4262 | MIR4263 | MIR4264 | MIR4265 | MIR4266 | MIR4267 | MIR4268 | MIR4269 | MIR4270 | MIR4271 | MIR4272